BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 31144789)

  • 1. Correlations of pathological stage and prognosis of NSCLC patients with changes in serum CEA and CYFRA 21-1 and CT characteristics.
    Zhao W; Liu Y; Kong F; Li Y
    Panminerva Med; 2020 Mar; 62(1):67-69. PubMed ID: 31144789
    [No Abstract]   [Full Text] [Related]  

  • 2. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
    Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
    Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between pretreatment levels of serum Cyfra 21.1, CEA and PET metabolic parameters in NSCLC.
    Dogan I; Karyagar S; Karyagar SS; Kahraman C; Alver A
    Ann Nucl Med; 2014 Nov; 28(9):829-35. PubMed ID: 24990528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
    Fiala O; Pesek M; Finek J; Benesova L; Minarik M; Bortlicek Z; Topolcan O
    Anticancer Res; 2014 Jun; 34(6):3205-10. PubMed ID: 24922695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer.
    Szturmowicz M; Rudziński P; Kacprzak A; Langfort R; Bestry I; Broniarek-Samson B; Orłowski T
    Pneumonol Alergol Pol; 2014; 82(5):422-9. PubMed ID: 25133810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance characteristics of an automated assay for the quantitation of CYFRA 21-1 in human serum.
    Patel JL; Erickson JA; Roberts WL; Grenache DG
    Clin Biochem; 2010 Dec; 43(18):1449-52. PubMed ID: 20875814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer.
    Zhang ZH; Han YW; Liang H; Wang LM
    Cancer Med; 2015 Nov; 4(11):1633-8. PubMed ID: 26333429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relevance of serum carcinoembryonic antigen as an indicator of brain metastasis detection in advanced non-small cell lung cancer.
    Lee DS; Kim YS; Jung SL; Lee KY; Kang JH; Park S; Kim YK; Yoo IeR; Choi BO; Jang HS; Yoon SC
    Tumour Biol; 2012 Aug; 33(4):1065-73. PubMed ID: 22351560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
    Sone K; Oguri T; Nakao M; Kagawa Y; Kurowaka R; Furuta H; Fukuda S; Uemura T; Takakuwa O; Kanemitsu Y; Ohkubo H; Takemura M; Maeno K; Ito Y; Sato H; Muramatsu H; Niimi A
    Anticancer Res; 2017 Feb; 37(2):935-939. PubMed ID: 28179355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
    Li L; Song LH; Ding SC; Zhang XJ; Qiang L; Han CY; Yuan XT; Xu DD
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer.
    Tomita M; Shimizu T; Ayabe T; Yonei A; Onitsuka T
    Anticancer Res; 2010 Jul; 30(7):3099-102. PubMed ID: 20683062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CEA, CYFRA21-1 and SCC in non-small cell lung cancer.
    Moro D; Villemain D; Vuillez JP; Delord CA; Brambilla C
    Lung Cancer; 1995 Oct; 13(2):169-76. PubMed ID: 8581396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
    Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
    Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score.
    Blankenburg F; Hatz R; Nagel D; Ankerst D; Reinmiedl J; Gruber C; Seidel D; Stieber P
    Tumour Biol; 2008; 29(4):272-7. PubMed ID: 18781099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
    Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
    Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer.
    Barlési F; Gimenez C; Torre JP; Doddoli C; Mancini J; Greillier L; Roux F; Kleisbauer JP
    Respir Med; 2004 Apr; 98(4):357-62. PubMed ID: 15080079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
    Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
    Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients.
    Muley T; Dienemann H; Ebert W
    Anticancer Res; 2004; 24(3b):1953-6. PubMed ID: 15274383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
    Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
    J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.